CN113413461A - Medicine for resisting senile dementia and its preparing method - Google Patents
Medicine for resisting senile dementia and its preparing method Download PDFInfo
- Publication number
- CN113413461A CN113413461A CN202110673846.1A CN202110673846A CN113413461A CN 113413461 A CN113413461 A CN 113413461A CN 202110673846 A CN202110673846 A CN 202110673846A CN 113413461 A CN113413461 A CN 113413461A
- Authority
- CN
- China
- Prior art keywords
- senile dementia
- growth factor
- nerve growth
- lentinan
- snake venom
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 91
- 208000024827 Alzheimer disease Diseases 0.000 title claims abstract description 75
- 206010039966 Senile dementia Diseases 0.000 title claims abstract description 72
- 229940079593 drug Drugs 0.000 title claims abstract description 62
- 238000000034 method Methods 0.000 title claims description 11
- 150000004676 glycans Chemical class 0.000 claims abstract description 41
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 41
- 239000005017 polysaccharide Substances 0.000 claims abstract description 41
- 108050009271 Venom nerve growth factor Proteins 0.000 claims abstract description 32
- 239000003998 snake venom Substances 0.000 claims abstract description 32
- 241001061264 Astragalus Species 0.000 claims abstract description 28
- 229920001491 Lentinan Polymers 0.000 claims abstract description 28
- 235000006533 astragalus Nutrition 0.000 claims abstract description 28
- 229940115286 lentinan Drugs 0.000 claims abstract description 28
- 210000004233 talus Anatomy 0.000 claims abstract description 28
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims abstract description 23
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 claims abstract description 23
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 claims abstract description 23
- 238000002360 preparation method Methods 0.000 claims abstract description 13
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 16
- 239000002552 dosage form Substances 0.000 claims description 15
- 230000007131 anti Alzheimer effect Effects 0.000 claims description 13
- 239000003826 tablet Substances 0.000 claims description 9
- 239000002775 capsule Substances 0.000 claims description 6
- 239000007924 injection Substances 0.000 claims description 6
- 238000002347 injection Methods 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 230000002335 preservative effect Effects 0.000 claims description 6
- 108010025020 Nerve Growth Factor Proteins 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 5
- 239000002270 dispersing agent Substances 0.000 claims description 5
- 239000000796 flavoring agent Substances 0.000 claims description 5
- 235000013355 food flavoring agent Nutrition 0.000 claims description 5
- 239000000314 lubricant Substances 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 239000003755 preservative agent Substances 0.000 claims description 5
- 239000003381 stabilizer Substances 0.000 claims description 5
- 239000002562 thickening agent Substances 0.000 claims description 5
- 241000272074 Bungarus Species 0.000 claims description 3
- 241000272060 Elapidae Species 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 3
- 239000007884 disintegrant Substances 0.000 claims description 3
- 229940124531 pharmaceutical excipient Drugs 0.000 claims description 3
- 241000271042 Gloydius halys Species 0.000 claims 1
- 102000015336 Nerve Growth Factor Human genes 0.000 claims 1
- 229940053128 nerve growth factor Drugs 0.000 claims 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 abstract description 18
- 229960004373 acetylcholine Drugs 0.000 abstract description 18
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 abstract description 14
- 230000002195 synergetic effect Effects 0.000 abstract description 10
- 210000004556 brain Anatomy 0.000 abstract description 9
- 229960003638 dopamine Drugs 0.000 abstract description 7
- 230000015654 memory Effects 0.000 abstract description 6
- 208000024891 symptom Diseases 0.000 abstract description 5
- 210000003414 extremity Anatomy 0.000 abstract description 4
- 230000000694 effects Effects 0.000 description 22
- 230000006870 function Effects 0.000 description 12
- 235000018102 proteins Nutrition 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 210000005036 nerve Anatomy 0.000 description 9
- 230000036039 immunity Effects 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 6
- 230000001713 cholinergic effect Effects 0.000 description 6
- 210000002540 macrophage Anatomy 0.000 description 6
- 230000008439 repair process Effects 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 235000019640 taste Nutrition 0.000 description 5
- 102000007072 Nerve Growth Factors Human genes 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000002932 cholinergic neuron Anatomy 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000001338 necrotic effect Effects 0.000 description 4
- 210000002569 neuron Anatomy 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 230000008929 regeneration Effects 0.000 description 4
- 238000011069 regeneration method Methods 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000036737 immune function Effects 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 2
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 2
- 108010011485 Aspartame Proteins 0.000 description 2
- 108010058699 Choline O-acetyltransferase Proteins 0.000 description 2
- 102100023460 Choline O-acetyltransferase Human genes 0.000 description 2
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241001474977 Palla Species 0.000 description 2
- 206010057249 Phagocytosis Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 235000021120 animal protein Nutrition 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000002155 anti-virotic effect Effects 0.000 description 2
- 230000010100 anticoagulation Effects 0.000 description 2
- 239000000605 aspartame Substances 0.000 description 2
- 235000010357 aspartame Nutrition 0.000 description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 2
- 229960003438 aspartame Drugs 0.000 description 2
- 210000003050 axon Anatomy 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 235000010418 carrageenan Nutrition 0.000 description 2
- 239000000679 carrageenan Substances 0.000 description 2
- 229920001525 carrageenan Polymers 0.000 description 2
- 229940113118 carrageenan Drugs 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000019771 cognition Effects 0.000 description 2
- 230000006957 competitive inhibition Effects 0.000 description 2
- 210000003792 cranial nerve Anatomy 0.000 description 2
- 239000000179 crotalid venom Substances 0.000 description 2
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000003086 effect on acetylcholine Effects 0.000 description 2
- 239000000686 essence Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 229910001385 heavy metal Inorganic materials 0.000 description 2
- 230000007236 host immunity Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 238000011031 large-scale manufacturing process Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000005461 lubrication Methods 0.000 description 2
- HBNDBUATLJAUQM-UHFFFAOYSA-L magnesium;dodecyl sulfate Chemical compound [Mg+2].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCOS([O-])(=O)=O HBNDBUATLJAUQM-UHFFFAOYSA-L 0.000 description 2
- 229960001855 mannitol Drugs 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 210000004126 nerve fiber Anatomy 0.000 description 2
- 230000002232 neuromuscular Effects 0.000 description 2
- 230000004693 neuron damage Effects 0.000 description 2
- 230000007514 neuronal growth Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000008782 phagocytosis Effects 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000001242 postsynaptic effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229940085605 saccharin sodium Drugs 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- -1 sodium bicarbonate Substances 0.000 description 2
- 229960001462 sodium cyclamate Drugs 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229940124810 Alzheimer's drug Drugs 0.000 description 1
- 244000247812 Amorphophallus rivieri Species 0.000 description 1
- 235000001206 Amorphophallus rivieri Nutrition 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 240000004355 Borago officinalis Species 0.000 description 1
- 235000007689 Borago officinalis Nutrition 0.000 description 1
- 101000946377 Bos taurus Alpha-lactalbumin Proteins 0.000 description 1
- 101000741065 Bos taurus Beta-casein Proteins 0.000 description 1
- 101001008231 Bos taurus Beta-lactoglobulin Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 1
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 1
- 206010008132 Cerebral thrombosis Diseases 0.000 description 1
- 206010052770 Coma states Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 208000034347 Faecal incontinence Diseases 0.000 description 1
- 101000609762 Gallus gallus Ovalbumin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 240000000950 Hippophae rhamnoides Species 0.000 description 1
- 235000003145 Hippophae rhamnoides Nutrition 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- 229920002752 Konjac Polymers 0.000 description 1
- 239000004395 L-leucine Substances 0.000 description 1
- 235000019454 L-leucine Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 240000006240 Linum usitatissimum Species 0.000 description 1
- 235000004431 Linum usitatissimum Nutrition 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- 244000241838 Lycium barbarum Species 0.000 description 1
- 235000015459 Lycium barbarum Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 244000090896 Nigella sativa Species 0.000 description 1
- 235000016698 Nigella sativa Nutrition 0.000 description 1
- 235000004347 Perilla Nutrition 0.000 description 1
- 244000124853 Perilla frutescens Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 235000009120 camo Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 235000005607 chanvre indien Nutrition 0.000 description 1
- 230000009920 chelation Effects 0.000 description 1
- 230000002925 chemical effect Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229940127243 cholinergic drug Drugs 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- MSBXTPRURXJCPF-DQWIULQBSA-N cucurbit[6]uril Chemical compound N1([C@@H]2[C@@H]3N(C1=O)CN1[C@@H]4[C@@H]5N(C1=O)CN1[C@@H]6[C@@H]7N(C1=O)CN1[C@@H]8[C@@H]9N(C1=O)CN([C@H]1N(C%10=O)CN9C(=O)N8CN7C(=O)N6CN5C(=O)N4CN3C(=O)N2C2)C3=O)CN4C(=O)N5[C@@H]6[C@H]4N2C(=O)N6CN%10[C@H]1N3C5 MSBXTPRURXJCPF-DQWIULQBSA-N 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 210000001787 dendrite Anatomy 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 235000004426 flaxseed Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 239000011487 hemp Substances 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 231100000405 induce cancer Toxicity 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 230000009191 jumping Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000000252 konjac Substances 0.000 description 1
- 235000010485 konjac Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229960003136 leucine Drugs 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229940037627 magnesium lauryl sulfate Drugs 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000007830 nerve conduction Effects 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 239000001711 nigella sativa Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229960000292 pectin Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000000331 sympathetic ganglia Anatomy 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The application belongs to the technical field of medicines, and particularly relates to an anti-senile dementia medicine and a preparation method thereof. Wherein the anti-senile dementia medicine comprises the following components by taking the total mass of the anti-senile dementia medicine as 100 percent: fucose 30% -60%; 10 to 40 percent of astragalus polysaccharide; 10 to 40 percent of lentinan; 20 to 50 percent of snake venom nerve growth factor. The application provides an anti-senile dementia medicine, through the synergistic effect of each component, has better treatment to senile dementia, can promote the acetylcholine release of four limbs trunk, leads to the acetylcholine and the dopamine balance in the brain, treats and alleviates senile dementia's symptom to and resume intelligence and memory to a certain extent.
Description
Technical Field
The application belongs to the technical field of medicines, and particularly relates to an anti-senile dementia medicine and a preparation method thereof.
Background
Senile dementia, known under the name of Alzheimer's Disease (AD), was described by the german doctor Alois Alzheimer's in 1906 as the common cause of dementia, with an increasing prevalence with age, about 5% in people over 65 years and about 20% in people over 85 years. With the aging population, the incidence of AD increases year by year, seriously harms physical and mental health and life quality of the old, causes profound pain to patients, brings heavy burden to families and society, becomes a serious social problem, causes general attention of governments and medical circles of various countries, and is an urgent problem of modern medical research. In the case of senile dementia, it is generally considered that only decline occurs progressively due to organic or metabolic lesions of the brain. Recently, it is considered that brain metabolism disorder, dopamine decrease, and increase of Acetylcholine (ACH) are caused by various diseases, and the brain function is unbalanced, and mental disorder and action retardation instructed by the brain occur. In particular, in recent years, lipid diet is increased, physical exercise is reduced, cerebral vascular acidification is formed, and the like, which causes extensive encephalatrophy, cerebral blood flow supply insufficiency and senile dementia.
At present, no specific medicine exists for treating senile dementia, and the anti-AD medicine in clinical application or clinical research is mainly used for improving the ACH level in cranial nerves, recovering ACH nerve conduction, improving the memory, cognition and behavior ability of patients and delaying the development of diseases. One class of drugs is the cholinergic drugs, and the other class of drugs is the drugs that promote the release of ACH in the cranial nerves. The commonly used prevention and treatment medicines comprise medicines for promoting blood circulation and removing blood stasis, central stimulant, substance for improving cholinergic property, cerebral blood circulation improver and the like, however, the medicines have the defects of uncertain curative effect, weak specificity or large toxic and side effect, and the like, and the treatment of symptoms and root causes is not treated, so the application of the medicines is limited.
Disclosure of Invention
The application aims to provide an anti-senile dementia medicament and a preparation method thereof, and aims to solve the problems of inaccurate curative effect, low specificity and large toxic and side effects of the existing anti-senile dementia medicament to a certain extent.
In order to achieve the purpose of the application, the technical scheme adopted by the application is as follows:
in a first aspect, the present application provides an anti-senile dementia drug, which comprises the following components, based on 100% of the total mass of the anti-senile dementia drug:
further, the medicine comprises the following components by taking the total mass of the anti-senile dementia medicine as 100 percent:
furthermore, in the anti-senile dementia medicine, the mass ratio of the astragalus polysaccharide to the lentinan is 1 (1-3).
Further, the snake venom nerve growth factor comprises at least one of bungarus venom nerve growth factor, Elapidae snake venom nerve growth factor, and Pallas pit Viper venom nerve growth factor.
Further, the mass ratio of the total mass of the fucose, the astragalus polysaccharide and the lentinan to the snake venom nerve growth factor is (2-4): 1.
further, the mass ratio of the total mass of the fucose, the astragalus polysaccharide and the lentinan to the snake venom nerve growth factor is 3: 1.
further, the anti-senile dementia drug also comprises a pharmaceutic adjuvant, wherein the pharmaceutic adjuvant accounts for 1-3% by mass.
Further, the pharmaceutic adjuvant comprises at least one of a stabilizer, a thickening agent, a dispersing agent, a preservative, a disintegrating agent, a diluent, a flavoring agent, a lubricant and an excipient.
Furthermore, the dosage form of the anti-senile dementia drug comprises at least one of tablets, injections and capsules.
In a second aspect, the present application provides a method for preparing a medicament for resisting senile dementia, comprising the steps of: mixing 30-60 parts of fucose, 10-40 parts of astragalus polysaccharide, 10-40 parts of lentinan and 20-50 parts of snake venom nerve growth factor, and preparing into pharmaceutically acceptable dosage forms.
Further, the step of preparing a pharmaceutically acceptable dosage form comprises: adding adjuvant acceptable in medical scope into the mixture of fucose, Astragalus polysaccharides, lentinan and snake venom nerve growth factor, and making into at least one of tablet, injection and capsule.
In the anti-Alzheimer's disease drug provided by the first aspect of the application, 20% -50% of snake venom nerve growth factors can act on the postsynaptic part, namely, the motor nerve terminal blocks neuromuscular transmission, has competitive inhibition effect on acetylcholine, and plays a role with choline acetyltransferase in a specific neuron region, thereby effectively preventing damage of central cholinergic nerve systems, promoting the synthesis of acetylcholine and the generation of neuron growth and regeneration, and further solving the problem of reduction of acetylcholine in vivo caused by cholinergic neuron damage of senile dementia patients. In addition, 30 to 60 percent of fucose; 10 to 40 percent of astragalus polysaccharide is plant polysaccharide, can be used as an immune promoter or a regulator, and simultaneously has the functions of resisting virus, tumors, aging, radiation, stress, oxidation and the like; 10% -40% of lentinan is microbial polysaccharide, it has effects of antivirus, antitumor, regulating immunity function and stimulating interferon formation, etc., can enhance host immunity function, the mixed polysaccharide formed from these three kinds of polysaccharides can be combined with protein to form polysaccharide protein, in which the fucose can be used as component of sugar chain in the glucoprotein, can be combined with plasma membrane of various cell surfaces, can promote acetylcholine and dopamine metabolism in brain of patient to reach balance, repair necrotic starch protein, repair and rebuild immunity function, can be combined with snake venom nerve growth factor to play synergistic action, and can effectively prevent central cholinergic nerve system from damaging. The anti-senile dementia drug provided by the application has a better treatment effect on senile dementia through the synergistic cooperation effect of all the components, can promote the release of acetylcholine of limbs and trunk, leads to the balance of acetylcholine and dopamine in brain, treats and relieves the symptoms of senile dementia, and can restore intelligence and memory to a certain extent.
According to the preparation method of the anti-senile dementia drug provided by the second aspect of the application, 30-60 parts of fucose, 10-40 parts of astragalus polysaccharide, 10-40 parts of lentinan and 20-50 parts of snake venom nerve growth factor are mixed and processed to prepare pharmaceutically acceptable dosage forms, the preparation method is simple, the process is simple and convenient, and the preparation method is suitable for industrial large-scale production and application.
Detailed Description
In order to make the technical problems, technical solutions and advantageous effects to be solved by the present application more clearly apparent, the present application is further described in detail below with reference to the embodiments. It should be understood that the specific embodiments described herein are merely illustrative of the present application and are not intended to limit the present application.
In this application, the term "and/or" describes an association relationship of associated objects, meaning that there may be three relationships, e.g., a and/or B, which may mean: a is present alone, A and B are present simultaneously, and B is present alone. Wherein A and B can be singular or plural. The character "/" generally indicates that the former and latter associated objects are in an "or" relationship.
In the present application, "at least one" means one or more, "a plurality" means two or more. "at least one of the following" or similar expressions refer to any combination of these items, including any combination of the singular or plural items. For example, "at least one (one) of a, b, or c," or "at least one (one) of a, b, and c," may each represent: a, b, c, a-b (i.e., a and b), a-c, b-c, or a-b-c, wherein a, b, and c may be single or plural, respectively.
It should be understood that, in various embodiments of the present application, the sequence numbers of the above-mentioned processes do not mean the execution sequence, some or all of the steps may be executed in parallel or executed sequentially, and the execution sequence of each process should be determined by its function and inherent logic, and should not constitute any limitation to the implementation process of the embodiments of the present application.
The terminology used in the embodiments of the present application is for the purpose of describing particular embodiments only and is not intended to be limiting of the application. As used in the examples of this application and the appended claims, the singular forms "a," "an," and "the" are intended to include the plural forms as well, unless the context clearly indicates otherwise.
The weight of the related components mentioned in the description of the embodiments of the present application may not only refer to the specific content of each component, but also represent the proportional relationship of the weight among the components, and therefore, the content of the related components is scaled up or down within the scope disclosed in the description of the embodiments of the present application as long as it is scaled up or down according to the description of the embodiments of the present application. Specifically, the mass in the description of the embodiments of the present application may be in units of mass known in the chemical industry, such as μ g, mg, g, and kg.
The first aspect of the embodiments of the present application provides an anti-alzheimer's disease drug, which comprises the following components, by taking the total mass of the anti-alzheimer's disease drug as 100%:
in the anti-Alzheimer's disease drug provided by the first aspect of the application, 20% -50% of snake venom nerve growth factors can act on the postsynaptic part, namely, the motor nerve terminal blocks neuromuscular transmission, has competitive inhibition effect on acetylcholine, and plays a role with choline acetyltransferase in a specific neuron region, thereby effectively preventing damage of central cholinergic nerve systems, promoting the synthesis of acetylcholine and the generation of neuron growth and regeneration, and further solving the problem of reduction of acetylcholine in vivo caused by cholinergic neuron damage of senile dementia patients. In addition, 30 to 60 percent of fucose; 10 to 40 percent of astragalus polysaccharide is plant polysaccharide, can be used as an immune promoter or a regulator, and simultaneously has the functions of resisting virus, tumors, aging, radiation, stress, oxidation and the like; 10% -40% of lentinan is microbial polysaccharide, it has effects of antivirus, antitumor, regulating immunity function and stimulating interferon formation, etc., can enhance host immunity function, the mixed polysaccharide formed from these three kinds of polysaccharides can be combined with protein to form polysaccharide protein, in which the fucose can be used as component of sugar chain in the glucoprotein, can be combined with plasma membrane of various cell surfaces, can promote acetylcholine and dopamine metabolism in brain of patient to reach balance, repair necrotic starch protein, repair and rebuild immunity function, can be combined with snake venom nerve growth factor to play synergistic action, and can effectively prevent central cholinergic nerve system from damaging. The anti-senile dementia drug provided by the embodiment of the application has a good treatment effect on senile dementia through the synergistic cooperation of the components, can promote the release of acetylcholine of limbs and trunk, leads to the balance of acetylcholine and dopamine in brain, treats and relieves symptoms of senile dementia, and can restore intelligence and memory to a certain extent.
In some embodiments, the anti-senile dementia drug comprises the following components by 100 percent of the total mass of the anti-senile dementia drug:
in the anti-senile dementia medicament in the embodiment of the application, the raw material components have better synergistic effect in the proportion, and have better curative effect on senile dementia. The fucoidin has multiple physiological activities of anticoagulation, blood fat reduction, chronic renal failure resistance, tumor resistance, virus resistance, tissue regeneration promotion, gastric ulcer inhibition, organism immunity enhancement and the like, and has physicochemical properties of heavy metal ion chelation, hydrophilicity and the like. In addition, the fucoidin has direct immunoregulation function on macrophages and T cells, has obvious pharmacological activities of anticoagulation, fibrinolysis promotion and the like, can induce cancer cell apoptosis, induce cell growth factor generation, promote cell growth, repair damaged or hypofunction organs and tissues and prevent thrombosis, also has good effects of reducing blood fat, blood sugar and cholesterol, is used as a binding agent and a suction resisting agent of metal ions, and can effectively reduce the absorption of harmful heavy metal ions such as lead and the like by a human body. Fucose, astragalus polysaccharide, lentinan and other plant polysaccharides can form proteoglycan with protein through covalent bond, exert biological function, and have the effects of regulating immunity, enhancing organism immunity, etc. Promoting the metabolism of acetylcholine and dopamine in brain of patients to reach balance, repairing necrotic starch protein, and repairing and reconstructing immunologic function; and can be combined with snake venom nerve growth factor to achieve synergistic effect, and effectively prevent central cholinergic nerve system damage.
In some embodiments, in the anti-alzheimer drug, the mass ratio of astragalus polysaccharide to lentinan is 1: (1-3). According to the embodiment of the application, the astragalus polysaccharide and the lentinan can improve the immunity of the organism by increasing the size of macrophages, have a certain relation with the concentration of the macrophage phagocytosis activity, and can promote the phagocytosis of the macrophages within a proper concentration range. Astragalus polysaccharides and lentinan can regulate macrophage function by regulating the secretion of cytokine and the activity of endoenzyme of macrophage. In addition, the astragalus polysaccharide and the lentinan can regulate the proliferation capacity, subgroup structure, cytokine secretion and the like of lymphocyte, improve the antibody level in the serum of animal organism, enhance the immune function of the organism, activate natural killer cells and enhance the killing activity of the natural killer cells. The mass ratio is 1: the astragalus polysaccharide and the lentinan in the step (1-3) have a better synergistic effect, and can enhance the immune function of an organism and improve the memory, cognition and behavior abilities of a patient. In some embodiments, the mass ratio of astragalus polysaccharides to lentinan is 1: 3.
in some embodiments, the snake venom nerve growth factor comprises at least one of bungarus venom nerve growth factor, Elapidae snake venom nerve growth factor, and Pallas pit Viper venom nerve growth factor. The snake venom nerve growth factors can induce the directional growth of nerve fibers, stimulate the development of cell bodies and dendrites, increase the density of nerve fiber innervating areas, promote the differentiation and development of neurons, increase the number of sensory nerves and sympathetic ganglia, increase the volume and prolong fibers, promote protein synthesis, sugar and lipid metabolism, promote the development of subcellular organelles, and particularly influence the expression and modification of structural and functional proteins closely related to nerve differentiation. Meanwhile, the snake venom nerve growth factors can maintain the requirement of axon regeneration after nerve injury, stimulate axon sprouting and synapse formation and promote the regeneration of nerve cells. Can cause the proliferation and the survival time of central cholinergic neurons to be prolonged, effectively protect the neurodegeneration caused by the damage of the cholinergic neurons, and improve the learning and cognitive functions. And can enhance specific and non-specific immune responses and modulate immune system function by affecting immune cell activity.
In some embodiments, the mass ratio of the total mass of fucose and plant polysaccharides to snake venom nerve growth factor is (2-4): 1. in the anti-senile dementia drug of the embodiment of the application, the mass ratio of the total mass of fucose, astragalus polysaccharide and lentinan to the mass of snake venom nerve growth factor is (2-4): 1, in some embodiments, the mass ratio of the total mass of fucose, astragalus polysaccharides, and lentinan to the snake venom nerve growth factor is 3: 1, the fucose, the plant polysaccharide and the snake venom nerve growth factor have the best synergistic effect in the mixture ratio.
In some embodiments, the anti-alzheimer disease drug further comprises a pharmaceutical adjuvant, and the pharmaceutical adjuvant accounts for 1-3% by mass. The anti-senile dementia drug further comprises a pharmaceutical adjuvant, and the drug can be prepared into different dosage forms according to actual application requirements through the matching of the auxiliary materials to be used. In some embodiments, the mass percentage of the pharmaceutical excipients may be 1%, 2%, 3%, etc.
In some embodiments, the pharmaceutical excipient comprises at least one of a stabilizer, a thickener, a dispersant, a preservative, a disintegrant, a diluent, a flavoring agent, a lubricant, and an excipient. The embodiment of the application has the advantages that the auxiliary materials are added into the medicinal auxiliary materials, so that the effects of disintegration, dilution, taste correction, lubrication, shaping and the like are achieved, the requirements of different preparations, tastes and the like are met, and the performances of the medicine such as use flexibility, taste, storage stability and the like are improved.
In some embodiments, the disintegrant is selected from: at least one of citric acid, sodium carbonate, sodium bicarbonate, sodium carboxymethyl starch and crospovidone, and these disintegrating agents can make the tablet rapidly break into fine particles in gastrointestinal fluid, so that the active substances in the anti-senile dementia drug can be rapidly dissolved and absorbed to exert drug effect.
In some embodiments, the diluent is selected from: dextrin sucrose, lactose, mannitol, and glucose. The diluent adopted by the embodiment of the invention has large medicine holding capacity, is used for increasing the weight and the volume of the tablet medicine, plays a filling role and is beneficial to forming of the pharmaceutical preparation.
In some embodiments, the flavoring agent is selected from: at least one of essence, mannitol, sorbitol, saccharin sodium, sodium cyclamate, aspartame, acesulfame-k essence, mannitol, sorbitol, saccharin sodium, sodium cyclamate, aspartame, and acesulfame-k. The flavoring agent adopted by the embodiment of the invention can better improve or shield the unpleasant smell and taste of the medicine, improve the taste of the medicine and enable patients to accept the medicine more easily.
In some embodiments, the lubricant is selected from: polyethylene glycol 6000, sodium dodecyl sulfate, magnesium dodecyl sulfate, L-leucine, and sodium benzoate. The lubricant adopted by the embodiment of the invention has the effects of glidant, anti-adhesion, lubrication and the like, and is beneficial to pharmaceutical preparation.
In some embodiments, the excipient is selected from: at least one of beeswax, guar gum, locust bean gum, konjac powder, carrageenan, lanolin, vaseline, polyethylene glycol, and magnesium lauryl sulfate. The excipient adopted by the embodiment of the invention has stable property, has no incompatibility with each active substance in the medicament, does not generate side effect, does not influence the curative effect, is harmless to human body, has no physiological effect, does not generate chemical or physical effect with each active substance of raw materials, and is not easy to deform, crack, mildew and the like at normal temperature.
In some embodiments, the stabilizing agent is selected from: xanthan gum, pectin, carrageenan, sodium carboxymethylcellulose, seaweed gel, cucurbituril, and animal protein. Wherein the animal protein is selected from one or more of bovine alpha-lactalbumin, bovine serum albumin, bovine beta-casein, bovine beta-lactoglobulin, fish skin gelatin, pig skin gelatin and chicken egg albumin. These stabilizers of the present application increase the stability of lycium barbarum, hippophae rhamnoides, nigella sativa seeds, almonds, hemp seeds, perilla seeds, wheat germs, borage and linseed in anti-senile dementia drugs.
In some embodiments, the thickening agent is selected from: the thickening agents can improve the viscosity of the system, keep the system in a uniform and stable suspension state or an opacified state, are beneficial to the formation of anti-senile dementia medicaments and are convenient to apply.
In some embodiments, the dispersant is selected from: at least one of vegetable oil, mineral oil and polyethylene glycol, and the dispersing agent can improve the mixing uniformity of the components in the composition.
In some embodiments, the preservative is selected from: the preservative has a good preservative effect, improves the storage stability of the anti-senile dementia drug, and prolongs the service life.
In some embodiments, the anti-alzheimer's disease drug dosage form comprises at least one of tablets, injections and capsules, and the dosage forms have wide application range and flexible application. In other embodiments, the composition can also be in the forms of oral liquid, paste, powder, granules, pills, suppositories and the like.
In some embodiments, the anti-senile dementia drug comprises the following components by 100 percent of the total mass of the anti-senile dementia drug:
the anti-senile dementia drug in the embodiment of the application can exert better curative effect through the synergistic effect of the components.
The anti-alzheimer's disease drug of the examples of this application can be prepared by the following methods of examples.
In a second aspect, the present application provides a method for preparing a medicament for resisting senile dementia, comprising the steps of: mixing 30-60 parts of fucose, 10-40 parts of astragalus polysaccharide, 10-40 parts of lentinan and 20-50 parts of snake venom nerve growth factor, and preparing into pharmaceutically acceptable dosage forms.
According to the preparation method of the anti-senile dementia drug provided by the second aspect of the application, 30-60 parts of fucose, 10-40 parts of astragalus polysaccharide, 10-40 parts of lentinan and 20-50 parts of snake venom nerve growth factor are mixed and processed to prepare a pharmaceutically acceptable dosage form, the preparation method is simple, the process is simple and convenient, and the preparation method is suitable for industrial large-scale production and application.
In some embodiments, the step of forming a pharmaceutically acceptable dosage form comprises: adding adjuvant acceptable in medical field into mixture of fucose, lentinan, Astragalus polysaccharides and snake venom nerve growth factor, and making into at least one of tablet, injection and capsule. The anti-senile dementia drug can be prepared into various dosage forms by adding different auxiliary materials, the preparation is flexible and convenient, no special limitation exists, the requirements of different dosage forms can be met, and the applicability is wide.
In order to make the above implementation details and operations clearly understood by those skilled in the art and to make the progress of the anti-alzheimer's disease drug and the preparation method thereof obviously appear in the examples of the present application, the above technical solutions are illustrated by a plurality of examples below.
Example 1
A medicine for resisting senile dementia is prepared by the following steps: mixing 35 parts of fucose, 20 parts of astragalus polysaccharide, 20 parts of lentinan and 25 parts of snake venom nerve growth factor, and making into tablet according to 500 microgram/granule of raw materials.
Further, in order to verify the advancement of the anti-senile dementia drugs of the examples of the present application, the following tests were performed on the anti-senile dementia drugs of the examples:
1. using the anti-senile dementia drug prepared in example 1 as an experimental group, setting three parallel experimental groups of 1 group, 2 groups and 3 groups, using physiological saline as a control group, administering the drug to experimental mice having symptoms of senile dementia by oral administration and intramuscular injection, recording the number of jumps of the mice after administration, and the test results are shown in the following table 1:
TABLE 1
From the test results, the anti-senile dementia drug prepared in the embodiment 1 of the application has the advantages that the number of jumping times is reduced after the drug is taken orally or through intramuscular injection, so that the drug can effectively inhibit the excitability of a nervous system, repair necrotic amyloid cells, regrow proteins and gradually recover memory. It is demonstrated that the anti-senile dementia drug prepared in example 1 of the present application shows a significant therapeutic effect on senile dementia. In addition, the P value of the anti-senile dementia drug prepared in the application example 1 is less than or equal to 0.01 in the test experiment, which shows that the error rate is low and the test result is close to real.
2. Clinical test of the anti-Alzheimer's disease drug prepared in example 1-clinical test
The medicine is administered to patients who are in a coma state, have limb movement disorder, have fever, can not speak, can not move, have incontinence of urine and feces at the time of admission, enter a vegetative state, and are clinically diagnosed as senile dementia.
The results show that: after the patient takes the anti-senile dementia drug in the embodiment 1 twice a day and two doses each time for 20 days, the mind can be recovered, and after the drug is taken for two months, the language can be recovered, and the meeting can be cleared.
3. Clinical test on the anti-Alzheimer's disease drug prepared in example 1
Is administered to patients with left cerebral thrombosis and vascular senile dementia.
The results show that: after the patient takes the anti-senile dementia drug in the embodiment 1 twice a day and two pills each time, the intelligence is active before half a month, the emotion is obviously active, after 2 months, the patient can speak, can walk and play, has good upper limb activity, can take care of people when meeting after three months, moves freely and has obvious improvement on self-care ability.
The above description is only exemplary of the present application and should not be taken as limiting the present application, as any modification, equivalent replacement, or improvement made within the spirit and principle of the present application should be included in the protection scope of the present application.
Claims (10)
3. the anti-senile dementia drug according to claim 2, wherein the mass ratio of the astragalus polysaccharide to the lentinan is 1 (1-3).
4. The anti-Alzheimer's disease drug according to any one of claims 1-3, wherein the snake venom nerve growth factor comprises at least one of bungarus venosus nerve growth factor, elapidae snake venom nerve growth factor, and Agkistrodon halys snake venom nerve growth factor.
5. The anti-senile dementia drug according to claim 4, wherein the mass ratio of the total mass of the fucose, the astragalus polysaccharide and the lentinan to the snake venom nerve growth factor is (2-4): 1;
and/or the mass ratio of the astragalus polysaccharide to the lentinan is 1: 3.
6. the anti-senile dementia drug according to claim 5, wherein the mass ratio of the total mass of fucose, the astragalus polysaccharide and the lentinan to the snake venom nerve growth factor is 3: 1;
and/or the anti-senile dementia medicine further comprises a pharmaceutic adjuvant, wherein the pharmaceutic adjuvant accounts for 1-3% by mass.
7. The anti-senile dementia drug according to claim 6, wherein the pharmaceutical excipients include at least one of a stabilizer, a thickener, a dispersant, a preservative, a disintegrant, a diluent, a flavoring agent, a lubricant, and an excipient.
8. The anti-senile dementia drug according to any one of claims 1 to 3 and 5 to 7, wherein the dosage form of the anti-senile dementia drug comprises at least one of a tablet, an injection and a capsule.
9. The preparation method of the anti-senile dementia medicine is characterized by comprising the following steps: mixing 30-60 parts of fucose, 10-40 parts of astragalus polysaccharide, 10-40 parts of lentinan and 20-50 parts of snake venom nerve growth factor, and preparing into pharmaceutically acceptable dosage forms.
10. The method of claim 9, wherein the step of formulating into a pharmaceutically acceptable dosage form comprises: adding adjuvant acceptable in medical scope into the mixture of fucose, Astragalus polysaccharides, lentinan and snake venom nerve growth factor, and making into at least one of tablet, injection and capsule.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110673846.1A CN113413461A (en) | 2021-06-17 | 2021-06-17 | Medicine for resisting senile dementia and its preparing method |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110673846.1A CN113413461A (en) | 2021-06-17 | 2021-06-17 | Medicine for resisting senile dementia and its preparing method |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113413461A true CN113413461A (en) | 2021-09-21 |
Family
ID=77788917
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110673846.1A Pending CN113413461A (en) | 2021-06-17 | 2021-06-17 | Medicine for resisting senile dementia and its preparing method |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113413461A (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114225011A (en) * | 2021-12-31 | 2022-03-25 | 宁夏医科大学总医院 | Compound preparation for preventing and treating GSM and application thereof |
CN115137746A (en) * | 2022-08-16 | 2022-10-04 | 暨南大学 | Application of lentinan in preparing medicine for preventing or treating neurodegenerative diseases |
CN115607563A (en) * | 2022-08-15 | 2023-01-17 | 江苏蓝果临床营养科技有限公司 | Nicotinamide mononucleotide complex and preparation method thereof |
WO2023057386A1 (en) * | 2021-10-04 | 2023-04-13 | Mjn U.S. Holdings Llc | Compositions for preventing and/or treating demyelination |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1104096A (en) * | 1993-12-22 | 1995-06-28 | 中国科学院昆明动物所动物毒素蛇资源开发中心 | Snake-poison substitute medicine for giving up drug-taking and curing senile dementia and its preparation method |
KR20050095796A (en) * | 2005-07-25 | 2005-10-04 | 학교법인 영남학원 | A health-supplementary food containing cordyceps ophioglossoides extract for improving damage of nerve cells and failure of memory induced by senile dementia |
CN103751207A (en) * | 2014-01-21 | 2014-04-30 | 新乡医学院 | Medicinal composition for treating Alzheimer's disease and application thereof |
CN111000984A (en) * | 2019-11-16 | 2020-04-14 | 祁展楷 | Application of snake nerve growth factor and snake nerve growth factor precursor in treating senile dementia |
-
2021
- 2021-06-17 CN CN202110673846.1A patent/CN113413461A/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1104096A (en) * | 1993-12-22 | 1995-06-28 | 中国科学院昆明动物所动物毒素蛇资源开发中心 | Snake-poison substitute medicine for giving up drug-taking and curing senile dementia and its preparation method |
KR20050095796A (en) * | 2005-07-25 | 2005-10-04 | 학교법인 영남학원 | A health-supplementary food containing cordyceps ophioglossoides extract for improving damage of nerve cells and failure of memory induced by senile dementia |
CN103751207A (en) * | 2014-01-21 | 2014-04-30 | 新乡医学院 | Medicinal composition for treating Alzheimer's disease and application thereof |
CN111000984A (en) * | 2019-11-16 | 2020-04-14 | 祁展楷 | Application of snake nerve growth factor and snake nerve growth factor precursor in treating senile dementia |
WO2021093134A1 (en) * | 2019-11-16 | 2021-05-20 | 祁展楷 | Use of group of snake nerve growth factors and snake nerve growth factor precursors in treatment of senile dementia |
Non-Patent Citations (3)
Title |
---|
朱怀荣,等: "《医用分子细胞生物学》", 人民卫生出版社, pages: 19 - 22 * |
李菲,等: "中药多糖治疗老年性痴呆及其机制研究进展", 中药药理与临床, no. 06, pages 203 - 208 * |
马国祥,等: "黄芪多糖对阿尔茨海默病模型大鼠的疗效及其作用机制研究", 卒中与神经疾病, vol. 24, no. 4, pages 323 - 327 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023057386A1 (en) * | 2021-10-04 | 2023-04-13 | Mjn U.S. Holdings Llc | Compositions for preventing and/or treating demyelination |
CN114225011A (en) * | 2021-12-31 | 2022-03-25 | 宁夏医科大学总医院 | Compound preparation for preventing and treating GSM and application thereof |
CN114225011B (en) * | 2021-12-31 | 2024-04-12 | 宁夏医科大学总医院 | Composite preparation for preventing and treating GSM and application thereof |
CN115607563A (en) * | 2022-08-15 | 2023-01-17 | 江苏蓝果临床营养科技有限公司 | Nicotinamide mononucleotide complex and preparation method thereof |
CN115607563B (en) * | 2022-08-15 | 2023-11-07 | 江苏蓝果临床营养科技有限公司 | Nicotinamide mononucleotide compound and preparation method thereof |
CN115137746A (en) * | 2022-08-16 | 2022-10-04 | 暨南大学 | Application of lentinan in preparing medicine for preventing or treating neurodegenerative diseases |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN113413461A (en) | Medicine for resisting senile dementia and its preparing method | |
EP2881112B1 (en) | Pharmaceutical composition for promoting nerve injury restoration and application thereof | |
CN109674958B (en) | Traditional Chinese medicine composition with effect of reducing uric acid and preparation method and application thereof | |
US6287576B1 (en) | Biostimulating agent | |
WO2008031322A1 (en) | Application of acetylcholine esterase inhibitor medication of leonurus extractive as cholinomimetic | |
US20220226413A1 (en) | Traditional chinese medicine composition with improving cognition effect, preparation method thereof and traditional chinese medicine preparation | |
CN108514109A (en) | Anaesthetize postoperative tailored version clinical nutrition formula and preparation method thereof | |
CN110772564A (en) | Traditional Chinese medicine extract composition with depression mood regulating effect, preparation method thereof and traditional Chinese medicine preparation | |
CN1257743C (en) | Composite gastrodia luber medicine and its preparation and use | |
CN112807292B (en) | Application of bunge auriculate root benzophenone in preparation of uric acid reducing medicines | |
CN116098918A (en) | Citicoline pharmaceutical composition and application thereof | |
CN101152223B (en) | Use of poplar leaf phenols extract in preparation of medicine for treating cardiovascular disease | |
CN112472725A (en) | Brown algae extract and its application | |
CN104826086A (en) | Senile dementia improvement polypeptide composition and preparation method and application thereof | |
CN112870212B (en) | Application of Anoectochilus roxburghii glycoside in preparation of medicine for preventing and/or treating pulmonary fibrosis | |
CN115624543B (en) | Medicine for treating migraine, pharmaceutical composition, preparation method and pharmaceutical application thereof | |
CN1248684C (en) | Chinese medicine powder for curing cardiovascular disease and preparing method thereof | |
TWI711449B (en) | Use of carnosic acid to prepare a pharmaceutical composition for treating abnormal involuntary movements induced by dopamine disorder disease | |
CN115381924B (en) | Composition for nerve repair and preparation method thereof | |
CN112807318B (en) | Application of 1,2,3,4, 6-O-pentagalloyl glucose in preparation of drugs for preventing and/or treating pulmonary fibrosis | |
CN106389439A (en) | Chinese and western medicine composition for curing liver cirrhosis ascites, and preparation method and application thereof | |
CN110193022B (en) | Application of chitosan oligosaccharide in improving lower limb ischemia caused by various diseases | |
CN118059145A (en) | Composition containing radix angelicae, preparation method thereof, traditional Chinese medicine preparation and application | |
CN110934996A (en) | Composition and preparation for treating mild dementia and application thereof | |
CN114732131A (en) | Composite hyaluronic acid composition for preventing and relieving joint diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |